The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Synthesis, Pharmacological Characterization, and Molecular Modeling of Heterobicyclic Amino Acids Related to (+)-2-Aminobicyclo[3.1.0]hexane- 2,6-dicarboxylic Acid (LY354740): Identification of Two New Potent, Selective, and Systemically Active Agonists for Group II Metabotropic Glutamate Receptors
Open accessAbstract
As part of our ongoing research program aimed at the identification of highly potent, selective, and systemically active agonists for group II metabotropic glutamate (mGlu) receptors, we have prepared novel heterobicyclic amino acids (-)-2-oxa-4-aminobicyclo[3.1. 0]hexane-4,6-dicarboxylate (LY379268, (-)-9) and (-)-2-thia-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY389795, (-)-10). Compounds (-)-9 and (-)-10 are structurally related to our previously described nanomolar potency group II mGlu receptor agonist, (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate monohydrate (LY354740 monohydrate, 5), with the C4-methylene unit of 5 being replaced with either an oxygen atom (as in (-)-9) or a sulfur atom (as in (-)-10). Compounds (-)-9 and (-)-10 potently and stereospecifically displaced specific binding of the mGlu2/3 receptor antagonist ([3H]LY341495) in rat cerebral cortical homogenates, displaying IC50 values of 15 +/- 4 and 8.4 +/- 0.8 nM, respectively, while having no effect up to 100 000 nM on radioligand binding to the glutamate recognition site on NMDA, AMPA, or kainate receptors. Compounds (-)-9 and (-)-10 also potently displaced [3H]LY341495 binding from membranes expressing recombinant human group II mGlu receptor subtypes: (-)-9, Ki = 14.1 +/- 1.4 nM at mGlu2 and 5.8 +/- 0.64 nM at mGlu3; (-)-10, Ki = 40.6 +/- 3.7 nM at mGlu2 and 4.7 +/- 1.2 nM at mGlu3. Evaluation of the functional effects of (-)-9 and (-)-10 on second-messenger responses in nonneuronal cells expressing human mGlu receptor subtypes demonstrated each to be a highly potent agonist for group II mGlu receptors: (-)-9, EC50 = 2.69 +/- 0.26 nM at mGlu2 and 4.58 +/- 0.04 nM at mGlu3; (-)-10, EC50 = 3.91 +/- 0.81 nM at mGlu2 and 7.63 +/- 2. 08 nM at mGlu3. In contrast, neither compound (up to 10 000 nM) displayed either agonist or antagonist activity in cells expressing recombinant human mGlu1a, mGlu5a, mGlu4a, or mGlu7a receptors. The agonist effects of (-)-9 and (-)-10 at group II mGlu receptors were not totally specific, however, as mGlu6 agonist activity was observed at high nanomolar concentrations for (-)-9 (EC50 = 401 +/- 46 nM) and at micromolar concentrations (EC50 = 2 430 +/- 600 nM) for (-)-10; furthermore, each activated mGlu8 receptors at micromolar concentrations (EC50 = 1 690 +/- 130 and 7 340 +/- 2 720 nM, respectively). Intraperitoneal administration of either (-)-9 or (-)-10 in the mouse resulted in a dose-related blockade of limbic seizure activity produced by the nonselective group I/group II mGluR agonist (1S,3R)-ACPD ((-)-9 ED50 = 19 mg/kg, (-)-10 ED50 = 14 mg/kg), indicating that these molecules effectively cross the blood-brain barrier following systemic administration and suppress group I mGluR-mediated limbic excitation. Thus, heterobicyclic amino acids (-)-9 and (-)-10 are novel pharmacological tools useful for exploring the functions of mGlu receptors in vitro and in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hollmann, M., & Heinemann, S. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.000335 · Cited by 3,975
Metabotropic glutamate receptors in brain function and pathology
Schoepp, D. D., & Conn, P. J. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90107-u · Cited by 791
Self-citationNakajima, Y., Iwakabe, H., Akazawa, C., Nawa, H., Shigemoto, R., Mizuno, N., & Nakanishi, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50280-0 · Cited by 739
Tanabe, Y., Nomura, A., Masu, M., Shigemoto, R., Mizuno, N., & Nakanishi, S. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-04-01372.1993 · Cited by 574
Molecular Diversity and Functions of Glutamate Receptors
Nakanishi, S., & Masu, M. (1994) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.bb.23.060194.001535 · Cited by 446
The glycine site of the NMDA receptor — five years on
Kemp, J. A., & Leeson, P. D. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90108-v · Cited by 436
DOHERTY, A. J., PALMER, M. J., HENLEY, J. M., COLLINGRIDGE, G. L., & JANE, D. E. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00001-4 · Cited by 312
Schoepp, D. D., Goldsworthy, J., Johnson, B. G., Salhoff, C. R., & Baker, S. R. (1994) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1994.63020769.x · Cited by 269
Self-citationSCHOEPP, D. D., JOHNSON, B. G., WRIGHT, R. A., SALHOFF, C. R., MAYNE, N. G., WU, S., COCKERHAM, S. L., PAUL BURNETT, J., BELEGAJE, R., BLEAKMAN, D., et al. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00160-8 · Cited by 225
Self-citationSills, M. A., Fagg, G., Pozza, M., Angst, C., Brundish, D. E., Hurt, S. D., Jay Wilusz, E., & Williams, M. (1991) · European Journal of Pharmacology · doi:10.1016/0014-2999(91)90063-v · Cited by 210
Cited by
Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation
Zonta, M., Angulo, M. C., Gobbo, S., Rosengarten, B., Hossmann, K.-A., Pozzan, T., & Carmignoto, G. (2003) · Nature Neuroscience · doi:10.1038/nn980 · Cited by 1,455
Pharmacological agents acting at subtypes of metabotropic glutamate receptors
Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00092-1 · Cited by 1,060
Self-citationIonotropic and metabotropic glutamate receptor structure and pharmacology
Kew, J. N. C., & Kemp, J. A. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2200-z · Cited by 788
Metabotropic glutamate receptors as novel targets for anxiety and stress disorders
Swanson, C. J., Bures, M., Johnson, M. P., Linden, A.-M., Monn, J. A., & Schoepp, D. D. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1630 · Cited by 607
Self-citationThe Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Schobel, S. A., Chaudhury, N. H., Khan, U. A., Paniagua, B., Styner, M. A., Asllani, I., Inbar, B. P., Corcoran, C. M., Lieberman, J. A., Moore, H., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.011 · Cited by 549
Stereoselective synthesis of quaternary α-amino acids. Part 1: Acyclic compounds
Cativiela, C., & Dı́az-de-Villegas, M. D. (1998) · Tetrahedron: Asymmetry · doi:10.1016/s0957-4166(98)00391-7 · Cited by 516
Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J., & Varney, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00652-8 · Cited by 432
Metabotropic glutamate receptors in the basal ganglia motor circuit
Conn, P. J., Battaglia, G., Marino, M. J., & Nicoletti, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1763 · Cited by 330
Marek, G. J., Wright, R. A., Schoepp, D. D., Monn, J. A., & Aghajanian, G. K. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35262-0 · Cited by 280
Self-citationRecent progress on the stereoselective synthesis of cyclic quaternary α-amino acids
Cativiela, C., & Ordóñez, M. (2009) · Tetrahedron: Asymmetry · doi:10.1016/j.tetasy.2009.01.002 · Cited by 276
Cartmell, J., Monn, J. A., & Schoepp, D. D. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35084-0 · Cited by 269
Self-citationG. Moloney, M. (1998) · Natural Product Reports · doi:10.1039/a815205y · Cited by 255
Liechti, M. E., Lhuillier, L., Kaupmann, K., & Markou, A. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-07.2007 · Cited by 193
Johnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W. J., Jagdmann, G. E., McKinzie, D. L., Nisenbaum, E. S., Tizzano, J. P., & Schoepp, D. D. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2099-9 · Cited by 156
Self-citation( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819540116 · Cited by 152
Caprioli, D., Venniro, M., Zeric, T., Li, X., Adhikary, S., Madangopal, R., Marchant, N. J., Lucantonio, F., Schoenbaum, G., Bossert, J. M., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.018 · Cited by 145
Caprioli, D., Justinova, Z., Venniro, M., & Shaham, Y. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.018 · Cited by 55
Scaccianoce, S., Matrisciano, F., Del Bianco, P., Caricasole, A., Di Giorgi Gerevini, V., Cappuccio, I., Melchiorri, D., Battaglia, G., & Nicoletti, F. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00027-3 · Cited by 54
Pozzi, L., Baviera, M., Sacchetti, G., Calcagno, E., Balducci, C., Invernizzi, R. W., & Carli, M. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2010.11.060 · Cited by 49
van Berckel, B. N. M., Kegeles, L. S., Waterhouse, R., Guo, N., Hwang, D.-R., Huang, Y., Narendran, R., Van Heertum, R., & Laruelle, M. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300902 · Cited by 43
Witkin, J. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172854 · Cited by 36
Metadata
- Authors
- Monn, J. A., Valli, M. J., Massey, S. M., Hansen, M. M., Kress, T. J., Wepsiec, J. P., Harkness, A. R., Grutsch, Wright, R. A., Johnson, B. G., Andis, S. L., Kingston, A., Tomlinson, R., Lewis, R., Griffey, K. R., Tizzano, J. P., & Schoepp, D. D.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-03-01
- Volume
- 42
- Issue
- 6
- Pages
- 1027-1040
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2085477113
- Cited by
- 293
- References
- 15
- FWCI
- 4.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.